Structural Characterization of a Noncovalent Complex between Ubiquitin and the Transactivation Domain of the Erythroid-Specific Factor EKLF  by Raiola, Luca et al.
Structure
ArticleStructural Characterization of a Noncovalent
Complex between Ubiquitin and the Transactivation
Domain of the Erythroid-Specific Factor EKLF
Luca Raiola,1 Mathieu Lussier-Price,1 David Gagnon,2 Julien Lafrance-Vanasse,1 Xavier Mascle,1 Genevieve Arseneault,1
Pascale Legault,1 Jacques Archambault,1,2 and James G. Omichinski1,*
1De´partement de Biochimie, Universite´ de Montre´al, C.P. 6128 Succursale Centre-Ville, Montre´al, QC H3C 3J7, Canada
2Institut de Recherches Cliniques de Montre´al, 110 Avenue des Pins Ouest, Montre´al, QC H2W 1R7, Canada
*Correspondence: jg.omichinski@umontreal.ca
http://dx.doi.org/10.1016/j.str.2013.08.027SUMMARY
Like other acidic transactivation domains (TAD), the
minimal TAD from the erythroid-specific transcrip-
tion factor EKLF (EKLFTAD) has been shown to
contribute both to its transcriptional activity as well
as to its ubiquitin(UBI)-mediated degradation. In
this article, we examine the activation-degradation
role of the acidic TAD of EKLF and demonstrate
that the first 40 residues (EKLFTAD1) within this
region form a noncovalent interaction with UBI.
Nuclear magnetic resonance (NMR) structural
studies of an EKLFTAD1-UBI complex show that
EKLFTAD1 adopts a 14-residue a helix that forms
the recognition interface with UBI in a similar manner
as the UBI-interacting helix of Rabex5. We also iden-
tify a similar interaction between UBI and the activa-
tion-degradation region of SREBP1a, but not with the
activation-degradation regions of p53, GAL4, and
VP16. These results suggest that select activation-
degradation regions like the ones found in EKLF
and SREBP1a function in part through their ability
to form noncovalent interactions with UBI.
INTRODUCTION
Ubiquitin (UBI) is a highly conserved protein that is found in all
eukaryotic organisms (Hershko et al., 2000). As a posttransla-
tional modification, UBI is covalently attached to the εNH2 group
of lysine residues in target proteins via an enzymatic pathway
that includes an E1-activating enzyme, an E2-conjugating
enzyme, and an E3-ligase (Hochstrasser, 2000; Pickart, 2001;
Weissman, 2001). Historically, posttranslational modifications
with UBI were considered to regulate protein levels by targeting
them for degradation. In protein degradation, target proteins are
modified with UBI or with poly-UBI chains containing four or
more UBIs branching from lysine 48 (K48) and this leads to their
recognition and proteolysis by the 26S proteasome (Elsasser
and Finley, 2005; Miller and Gordon, 2005). Over the last several
years, it has been shown that posttranslational modification with
either UBI or various forms of poly-UBI at one of several different2014 Structure 21, 2014–2024, November 5, 2013 ª2013 Elsevier Ltdlysine residues on UBI can play important roles in regulating a
number of other cellular functions in addition to degradation
(Geng et al., 2012; Haglund and Dikic, 2005; Ulrich, 2012).
One important feature that enables UBI to play important roles
in cellular regulation is its ability to function in noncovalent
protein-protein interaction through interactions with proteins
containing UBI-binding domains (UBD) (Dikic et al., 2009; Hurley
et al., 2006; Winget and Mayor, 2010). Given the ubiquitous
occurrence of UBI throughout cells, a number of different UBD
have been identified (for a review see Dikic et al., 2009). Several
of these UBDs contain helices that form the interface through
recognition of a hydrophobic patch formed by Leu8, Ile44, and
Val70 of UBI (Dikic et al., 2009; Hurley et al., 2006; Winget and
Mayor, 2010). As a protein interaction module, UBI can
interact with UBDs either as free UBI or as a fusion protein.
Because UBI can itself be polyubiquitinated at numerous
different lysine residues (6, 11, 23, 27, 29, 33, 48, and 63), it
has been proposed that by using different combinations
of poly-UBI branching patterns the potential number of
functions regulated through interactions with UBI is virtually
unlimited (Ikeda and Dikic, 2008) and UBI has been shown to
regulate cell-signaling pathways, DNA repair pathways, and
transcription (Geng et al., 2012; Haglund and Dikic, 2005; Ulrich,
2012).
The role that UBI plays in transcriptional regulation has been
extensively investigated over the last several years (Geng
et al., 2012). Based on these studies, it is now evident that UBI
functions in a number of different manners to regulate transcrip-
tion. Initial studies demonstrated that polyubiquitination and
degradation through the ubiquitin-proteosome system (UPS)
functioned as a straightforward process for tightly regulating
levels of transcription factors (Kubbutat et al., 1997). However,
the crucial role of UBI in transcription regulation became more
evident when a direct correlation was established between the
ability of many proteins to activate transcription and their post-
translational modification with UBI (Molinari et al., 1999). These
studies established that several transcriptional activators con-
tained a ‘‘degron region’’ that targets them for destruction via
the UPS and that this ‘‘degron region’’ overlappedwith their tran-
scriptional activation domain (TAD) (Salghetti et al., 2000, 2001).
Additional studies indicated that the function of the overlapping
activation-degradation region in regulating transcription is
extremely complex involving a number of different mechanisms
depending on the activator involved (Geng et al., 2012). ForAll rights reserved
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The Acidic TAD of EKLF Directly Binds Ubiquitinexample, acidic TADs from p53, herpes simplex viral protein 16
(VP16), and GAL4 appear to directly associate with a specific
UBI E3-ligase and this leads directly to their ubiquitination, acti-
vation, and degradation (Archer et al., 2008; Haupt et al., 1997;
Kubbutat et al., 1997; Le Cam et al., 2006; Muratani et al.,
2005; Salghetti et al., 2001). In the case of sterol regulatory
enhancer binding protein 1a (SREBP1a), both the acidic TAD
and the DNA-binding domain function as ‘‘degron regions,’’
and binding of the E3-ligase F-box and W-repeat domain-
containing 7 (Fbw7) occurs subsequent to a DNA-binding-
dependent phosphorylation reaction (Bengoechea-Alonso and
Ericsson, 2009; Sundqvist et al., 2005; Sundqvist and Ericsson,
2003). The results from these studies have led to a number of
different hypotheses for explaining the overlapping activation/
degradation function of TADs, and it is now clear that different
mechanisms are most likely involved depending on the pathway
(Geng et al., 2012).
Like a number of other factors that regulate hematopoietic
development, it has been previously shown that the erythroid-
Kru¨ppel-like factor (EKLF) is posttranslationally modified by UBI
on several lysine residues, and UBI-mediated degradation plays
an important role in regulating its turnover (Quadrini and Bieker,
2006). EKLF (also referred to as KLF1) is a member of the
Kru¨ppel-like protein family that is characterized by the presence
of threeCys2His2 zinc-finger domains at the extremecarboxy ter-
minus of the protein (Miller and Bieker, 1993). Functionally, EKLF
is an erythroid-specific transcription factor that plays a key role in
red blood cell development, in part by enhancing b-globin gene
expression through binding to CACCC-consensus sequences
located in thepromoter regionof the gene (Geng et al., 2012).Mu-
tations in either the zinc-finger domains of EKLF or the CACCC
sequences in the b-globin promoter regions result in a decrease
in b-globin expression underlying a number of blood cell-related
diseases (Feng et al., 1994; Perkins et al., 1995). In addition to the
three zinc-finger domains, EKLF contains a unique bipartite acti-
vation that includes a minimal TAD located in the amino-terminal
90 amino acids (Chen and Bieker, 1996). This minimal TAD of
EKLF can be further subdivided into two independent domains
EKLFTAD1 (residues 1–40) and EKLFTAD2 (residues 51–90)
that are both capable of independently activating transcription
(Chen and Bieker, 1996). EKLFTAD1 and EKLFTAD2 are both
highly acidic and contain a PEST (sequence rich in proline,
glutamic acid, serine, and threonine) region (Quadrini and
Bieker, 2006). Recent studies have demonstrated that deletion
of either PEST regions, especially the PEST1 region within
EKLFTAD1, significantly retards ubiquitin-mediated degradation
of EKLF without lowering the overall ubiquitination of EKLF
(Quadrini and Bieker, 2006). These results suggest that the mini-
mal TAD of EKLF has an overlapping activation/degradation
function that is critical to the role of EKLF in red blood cell
development.
Although it has been clearly demonstrated that EKLF is
degraded in a ubiquitin-dependent manner that requires the
PEST1 region within the minimal TAD (Quadrini and Bieker,
2006), there is very little known regarding the function the TAD
of EKLF plays in its UBI-mediated degradation. In this article,
we establish that UBI forms a direct noncovalent interaction
with the minimal TAD of EKLF that requires residues within the
PEST1 region of EKLFTAD1. NMR structural characterizationStructure 21, 2014–20of an EKLFTAD1-UBI complex demonstrates that a 14-residue
amphipathic helix in EKLFTAD1 forms the recognition interface
with UBI through interactions with a hydrophobic patch formed
by Leu8, Ile44, and Val70. The structure of EKLFTAD1 in com-
plex with UBI indicates that the helix is strikingly similar to the
helix of the motif-interacting with ubiquitin (MIU) domain of
Rabex-5 bound to UBI (Lee et al., 2006; Penengo et al., 2006).
NMR titration studies with other overlapping activation-degrada-
tion regions from p53, GAL4, VP16, and SREBP1a indicates that
binding of activation-degradation regions to UBI is not a univer-
sal attribute, because only the region from SREBP1a appears to
form a noncovalent interaction with UBI. Together, these
results suggest that the activation-degradation regions of EKLF
and SREBP1a function in similar manners through noncovalent
interactions with UBI and that their role in degradation is distinct
from the role of similar activation-degradation regions of p53,
VP16, and GAL4, which function by directly binding to UBI
E3-ligases.
RESULTS
EKLFTAD1 Binds Noncovalently to UBI
Although earlier studies indicated that deletion of either of the
two PEST regions significantly retards EKLF degradation, it
appeared that the PEST1 region (residues 32–52 in human
EKLF) plays a more significant role than the PEST2 region (resi-
dues 54–67) (Quadrini and Bieker, 2006). Interestingly, both
EKLFTAD1 (residues 1–40) and EKLFTAD2 (residues 50–90)
are composed predominantly of acidic and hydrophobic amino
acid residues, and the spacing pattern of the hydrophobic resi-
dues is surprisingly similar to what is observed in the sequences
of known ubiquitin interacting motifs (UIMs) and motifs interact-
ing with ubiquitin (MIUs) (Dikic et al., 2009). Given this sequence
similarity between EKLFTAD1/EKLFTAD2 and UIMs/MIUs and
the fact that the minimal EKLFTAD functions as an activation-
degradation region, we were interested to determine if the
minimal EKLFTAD is capable of forming a direct noncovalent
protein-protein interaction with UBI. To test the direct interaction
of the EKLFTAD with UBI, NMR chemical shift perturbation
studies were performed (Figure 1 and Figure S1 available online).
In these experiments, the addition of unlabeled UBI to 15N-
labeled EKLFTAD1 (Figures 1A and 1C), 15N-labeled EKLFTAD2
(Figure S1) or 15N-labeled EKLFTAD (Figures 1B and 1D) causes
significant changes in both the 1H and 15N chemical shifts for
several signals in the 1H-15N-HSQC spectrums. In the titration
with the full minimal EKLFTAD, the signals that undergo the
most significant chemical shift changes correspond to residues
in the EKLFTAD1 subdomain (Figure 1). In contrast, the signals
that correspond to residues in the EKLFTAD2 subdomain
undergo only very minor chemical shift changes in the titration
(Figure S1). Quantitative analysis of the chemical shift changes
occurring during the titrations indicates that EKLFTAD1 and
the EKLFTAD2 subdomain bind to UBI with apparent dissocia-
tion constants of 300 mM and 1.5 mM, respectively. Taken
together, the results indicate that the minimum EKLFTAD binds
directly to UBI and that residues in the EKLFTAD1 subdomain
form the interface with UBI with similar affinity as measured for
other UIMs/MIUs (Lee et al., 2006; Penengo et al., 2006; Swan-
son et al., 2003).24, November 5, 2013 ª2013 Elsevier Ltd All rights reserved 2015
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Figure 1. The TAD of EKLF Binds to UBI
(A and B) Overlay of the 2D 1H-15N HSQC spectra
of 15N-labeled EKLFTAD1 (A) and 15N-labeled
EKLFTAD (B) in the free form (black) and in
the presence of one (pink), two (blue), three
(orange), four (green), and five (red) molar equiva-
lents of UBI.
(C and D) The side chain of Trp (Hε1) from the
titrations with 15N-labeled EKLFTAD1 and 15N-
labeled EKLFTAD are shown in (C) and (D)
respectively.
See also Figure S1.
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The Acidic TAD of EKLF Directly Binds UbiquitinUBI Interacts Noncovalently with EKLFTAD1
Several structures of UBI in noncovalent complexes with
different binding partners demonstrate that the most common
interaction interface of UBI is a hydrophobic patch formed by
Leu8-Ile44-Val70 (Dikic et al., 2009; Hurley et al., 2006; Winget
and Mayor, 2010). To determine if EKLFTAD1 also interacts
with this hydrophobic patch, NMR chemical shift perturbation
studies were performed with unlabeled EKLFTAD1 and either
15N-labeled UBI or 15N/13C-labeled UBI. Addition of unlabeled
EKLFTAD1 to 15N-labeled UBI causes significant changes
in the 1H and 15N chemical shifts for several signals in the
1H-15N-HSQC spectrum of UBI (Figure 2A). Likewise, addition
of unlabeled EKLFTAD1 to 15N/13C-labeled UBI causes signifi-
cant changes in the 1H and 13C chemical shifts for several signals
in the 1H-13C-HSQC spectrum of UBI (Figure 2B). Consistent
with what is observed with UIMs/MIUs binding to UBI (Dikic
et al., 2009; Hurley et al., 2006; Winget and Mayor, 2010), the
most significant chemical shift changes in the 1H-15N-HSQC
spectrum of 15N-labeled UBI are centered around three distinct
regions between Thr7–Thr14 (L1 and b2), Leu43–Glu51 (b3, L3,
and b4), and Leu67–Leu73 (b5 and C terminus) (Figures 2C and
2D). The role of the Leu8-Ile44-Val70 patch is further supported
by the fact that significant 1H and 13C chemical shift changes in2016 Structure 21, 2014–2024, November 5, 2013 ª2013 Elsevier Ltd All rights reservedthe 1H-13C HSQC spectrum are observed
for the signals of the Hd1 and Hg2 of Ile44,
the Hg1 andHg2 of Val70, and the Hd1 and
Hd2 of Leu8 upon addition of EKLFTAD1
(Figure 2B).
NMR Structure Determination of
the UBI-EKLFTAD1 Complex
Given that EKLFTAD1 binds to the Leu8-
Ile44-Val70 patch of UBI, the NMR
solution structure of the EKLFTAD1-UBI
complex was determined in order to
compare it with structures of other
UIMs/MIUs in complex with UBI. The
NMR structure of the EKLFTAD1-UBI
complex is well defined by the NMR
data (Table 1). The 20 lowest-energy
structures are characterized by good
backbone geometry, no significant re-
straint violation, and low pairwise root
mean-square deviation (rmsd) values
(Figure 3A). The structures were calcu-lated using a total of 1,792 nuclear Overhauser effect (NOE)-
derived distance restraints including 15 intermolecular NOEs,
39 hydrogen-bond restraints, and 100 dihedral angle restraints.
A total of 100 structures were calculated and all of them satisfy
the experimental constraints with no NOE violation >0.2 A˚ and
no backbone angle violation >2 (Table 1).
Overall Structure of the EKLFTAD1-UBI Complex
The structure of UBI in complex with EKLFTAD1 is a typical UBI
fold that consists of a 12-residue a helix (H1), a short 3(10) helix
(H2), and a five-stranded mixed b sheet (b1–b5) (Vijay-Kumar
et al., 1985) (Figures 3A and 3B). EKLFTAD1 is disordered in
the complex with the exception of a 14-residue amphipathic a
helix that forms between residues Thr23 and Ala36 upon binding
UBI (Figure 3B). Consistent with the chemical shift mapping
results, the EKLFTAD1 helix forms an interface with UBI on a sur-
face that includes L1, b3, L3, b5, and the C terminus that are all
within the Leu8-Ile44-Val70 patch. Likewise, the signals for
residues that form the a helix in EKLFTAD1 undergo the most
significant chemical shift changes when UBI is added. With the
exception of the 14-residue a helix, EKLFTAD1 is disordered
and this transition of a short region from a disordered to an
ordered conformation is consistent with what has been observed
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Figure 2. EKLFTAD1 Binds the Leu8-Ile44-
Val70 Hydrophobic Patch of UBI
(A) Overlay of the 2D 1H-15N HSQC spectra of
15N-labeled UBI in the free form (black) and in the
presence of one (pink), two (blue), three (orange),
four (green), and five (red) molar equivalents of
EKLFTAD1.
(B) Overlay of the methyl region from 2D 1H-13C
HSQC spectra of 15N/13C-labeled UBI in the free
form (black) and in the presence of five (red) molar
equivalents of EKLFTAD1. Black arrows indicate
signals from methyl groups located in the Leu8-
Ile44-Val70 patch of UBI.
(C) Histogram of the variation in chemical shift
[Dd(ppm)] observed in the 2D 1H-15N HSQC
spectrum of UBI upon addition of EKLFTAD1.
(D) Molecular surface (cyan) of free UBI (PDB
accession code: 1UBQ). The residues showing
significant changes in chemical shifts in the 2D
1H-15NHSQC and 2D 1H-13CHSQC of 15N-labeled
and 15N/13C-labeled UBI upon formation of
the EKLFTAD1-UBI complex are highlighted
(magenta).
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The Acidic TAD of EKLF Directly Binds Ubiquitinfor several other acidic TADs upon binding to other target pro-
teins (Di Lello et al., 2006; Ferreon et al., 2009; Langlois et al.,
2008; Wojciak et al., 2009).
As described above, the interface of the EKLFTAD1-UBI com-
plex is predominantly formed through interactions involving the
amphipathic a helix of EKLFTAD1 and the Leu8-Ile44-Val70
hydrophobic patch of UBI. Like the interaction of the MIU of
Rabex5 with UBI (Lee et al., 2006; Penengo et al., 2006), the helix
of EKLFTAD1 binds in the reverse orientation as to what is
observed with UIMs binding to UBI (Swanson et al., 2003) (Fig-
ure 4). Three hydrophobic residues from the hydrophobic face
of the helix of EKLFTAD1 (Phe27, Leu28, and Trp31) appear
along the recognition interface, and Leu28 and Trp31 appear
to contribute significantly to the interaction with UBI (Figure 4A).
In the complex, the side chain of Leu28 is inserted into a pocket
formed by Lys6, Leu8, Ile44, His68, and Val70 of UBI where it is in
position to form methyl-methyl contacts with the side chains of
Ile44 and Val70 of UBI (Figure 4B). Trp31 is the second key res-
idue of EKLFTAD1 at the recognition interface with UBI. The
aromatic side chain of Trp31 inserts into a shallow pocket that
is formed by Leu8, Arg42, Ile44, Gln49, Val70, and Arg72 ofStructure 21, 2014–2024, November 5, 2013 ªUBI (Figure 4C), where it forms several
van der Waals contacts with methyl
groups of Leu8, Ile44, and Val70 from
UBI. In this orientation, the indole ring of
Trp31 is also in position to form a
cationic-p interaction with the side chain
of Arg42 from UBI. In the case of Phe28
of UBI, it appears to play a minor role in
the binding to UBI through an interaction
between its aromatic side chain and the
Hg methyl group of Ile44.
In addition to hydrophobic interactions,
the negatively charged residues from
EKLFTAD1 are in position to form several
potential ionic interactions with positivecharges on UBI in the NMR structures. In particular, Asp25 at
the N-terminal end of the a helix of EKLFTAD1 is in position to
form a salt bridge with Lys6 of UBI (Figures 4B and S2). Likewise,
Glu34 and Glu35 at the C-terminal end of the a helix of
EKLFTAD1 are in position to form ionic interactions with a posi-
tively charged surface formed by Arg42, Arg72, and Arg74 of UBI
(Figures 4C and S2). These potential electrostatic interactions at
both ends of the EKLFTAD1 helix function to establish the orien-
tation of the a helix on the UBI surface.
Mutational Studies of the EKLFTAD1 Interaction
with UBI
The NMR solution structure of the EKLFTAD1-UBI complex
demonstrates that the recognition interface is formed through in-
teractions between the hydrophobic face of the EKLFTAD1
amphipathic a helix andUBI (Figures 3 and 4). To assess the rela-
tive contributions of key residues of the EKLFTAD1 a helix, we
performed mutagenesis at several positions. Three EKLFTAD1
point mutants (F27S, L28S, and W31S) were generated, and
the binding of the variant proteins to UBI was tested by NMR
chemical shift perturbation experiments. In each experiment,2013 Elsevier Ltd All rights reserved 2017
Table 1. NMR and Refinement Statistics for EKLFTAD1-UBI
Complex
EKLFTAD1-UBI
NMR Distance and Dihedral Constraints
Distance constraints
Total NOE 1,877
Intraresidue 764
Interresidue
Sequential (ji – jj = 1) 460
Medium range (ji – jj < 4) 222
Long range (ji – jj > 5) 412
Intermolecular 19
Hydrogen bonds 38
Total dihedral angle restraints 100
f 50
c 50
Structure Statistics
Violations (mean and SD)
Distance constraints (A˚) 0.0106 ± 0.0006
Dihedral angle constraints () 0.226 ± 0.018
Maximum dihedral angle violation () 2.2
Maximum distance constraint violation (A˚) 0.22
Deviations from idealized geometry
Bond lengths (A˚) 0.00184 ± 0.00007
Bond angles () 0.362 ± 0.005
Impropers () 0.228 ± 0.010
Average pairwise rmsd (A˚)a
Heavy 1.30 ± 0.10
Backbone 0.56 ± 0.10
Ramachandran statistics (%)b
Residues in most favored regions 72.2
Residues in additional allowed regions 25.2
Residues in generously allowed regions 2.0
Residues in disallowed regions 0.6
The 20 conformers with the lowest energies were selected for statistical
analysis.
aOnly residues 3–72 of UBI and residues 24–35 of EKLFTAD1 were used
for the rmsd calculations. Residues at the N terminus (1–3) and at the
C terminus (73–76) of UBI, as well as residues at the N terminus (1–23)
and at the C terminus (36–40) of EKLFTAD1 were not included in the
calculation.
bBased on PROCHECK-NMR analysis.
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The Acidic TAD of EKLF Directly Binds Ubiquitinunlabeled UBI was incrementally added to the 15N-labeled
EKLFTAD1 variants as described in the previous section. During
these three titrations, we were not able to reach saturation or
determine values for the dissociation constants. Furthermore,
after addition of UBI to variant (F27S, L28S, and Trp31S)
EKLFTAD1 proteins, the resulting 1H-15N HSQC spectrums
were very similar to that of their free form (Figure S3). These re-
sults confirm that Phe27, Leu28, and Trp31 on the hydrophobic
face of the EKLFTAD1 a helix are crucial for binding to UBI. The
structure of the EKLFTAD1-UBI complex also indicates that
the Leu8-Ile44-Val70 hydrophobic patch of UBI establishes the
recognition interface with EKLFTAD1. To examine the contribu-2018 Structure 21, 2014–2024, November 5, 2013 ª2013 Elsevier Ltdtion of this hydrophobic patch, we used NMR chemical shift
perturbations experiments to test the binding of an I44A variant
of UBI (UBI44A), because this variation has been shown to
disrupt the binding of UIMs/MIUs to UBI (Shih et al., 2002). In
this experiment, unlabeled UBI44A was incrementally added to
the 15N-labeled EKLFTAD1. As observed with UIMs binding
to UBI, addition of the unlabeled I44A variant to 15N-labeled
EKLFTAD1 fails to induce significant changes in either the 1H
or 15N chemical shifts of the 2D 1H-15N-HSQC spectrum of
EKLFTAD1 (Figure S4). Taken together, these experiments with
variant proteins clearly demonstrate that the noncovalent inter-
action between EKLFTAD1 and UBI is very specific.
The Role of the UBI-Interacting Region of EKLFTAD1 in
EKLF Stability
Previous studies have shown that EKLF is degraded in a ubiqui-
tin-mediated manner and that the two PEST domains within the
minimal TAD play an important function in this pathway. In an
attempt to more quantitatively assess the role of the UBI-inter-
acting domain from EKLF in regulating its stability, we employed
a luciferase-based stability assay where variant EKLF proteins
are expressed in fusion with Renilla luciferase (RLuc) and
compared the steady-state level of wild-type EKLF (Mesple`de
et al., 2012). Three EKLF constructs were tested with RLuc fused
to the C terminus; the first construct encoded for full-length
human EKLF (EKLF-RLuc), the second encoded for EKLF with
a deletion of the full minimal TAD (DTAD-EKLF-RLuc), and the
third encoded for EKLF with serine substituted for F27, L28,
and W31 (F27S/L28S/W31S-EKLF). Increasing concentrations
of the EKLF-RLuc, DTAD-EKLF-RLuc, or F27S/L28S/W31S-
EKLF vectors were transfected into human C33a cells and
luciferase levels weremeasured 24 hr after transfection. As an in-
ternal control, a constant amount of a firefly luciferase (FLuc)
expression vector was used to normalize for transfection effi-
ciency and cell viability. As expected, the RLuc/FLuc ratio of
each construct was found to increase linearly as a function of
the five different concentrations of EKLF expression vector
tested (Figure 5A). Linear regression analysis of this data was
used to calculate a slope indicative of the stability of each
EKLF constructs. Under these assay conditions, the levels of
the EKLF-RLuc protein were slightly more than 2-fold lower
than both the DTAD-EKLF-RLuc and the F27S/L28S/W31S-
EKLF proteins (Figure 5B). In addition, the levels of the DTAD-
EKLF-RLuc and the F27S/L28S/W31S-EKLF proteins were
very similar. These results are in agreement with earlier studies
showing that the PEST1 region within the minimal TAD of EKLF
plays a significant role in ubiquitin-mediated degradation of
EKLF (Quadrini and Bieker, 2006) and further establishes that
the UBI-interacting domain in EKLF plays an important role in
regulating its steady-state levels.
The Activation-Degradation Region of SREBP1a
Binds UBI
Given that EKLFTAD1 can bind directly to UBI in amanner similar
to the MIU of Rabex-5 (Lee et al., 2006; Penengo et al., 2006),
we were interested to determine if other well-characterized
activation-degradation regions can also form a direct noncova-
lent interaction with UBI (Salghetti et al., 2000). To test this,
NMR chemical shift perturbation studies were performed withAll rights reserved
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Figure 3. Structure of the EKLFTAD1-UBI
Complex
(A) Overlay of the 20 lowest-energy structures of
the complex between UBI (cyan) and the UBI-
interacting helix of EKLFTAD1 (magenta). The
structures were superimposed using backbone
atoms C0, Ca, and N of residues 2–74 of UBI and
residues 23–36 of EKLFTAD1.
(B) Ribbon model of the lowest-energy conformer
of the complex betweenUBI (cyan) and EKLFTAD1
(magenta).
Structure
The Acidic TAD of EKLF Directly Binds Ubiquitinactivation-degradation regions from the TAD of p53 (p53TAD1;
residues 1–40), SREBP-1a (SREBP-1aTAD; residues 1–50),
VP16 (VP16N; residues 412–456), and GAL4 (GAL4TAD; resi-
dues 857–881) (Salghetti et al., 2000; Sundqvist and Ericsson,
2003) (Figures 6 and S5). These four TADs were chosen because
their sequences all contain a region with significant homology to
the region of EKLFTAD1 that forms the recognition interface with
UBI (Figure S6). The four TADs were 15N-labeled and their bind-
ing to unlabeled UBI was monitored by NMR chemical shift
perturbation experiments. As observed with EKLFTAD1 (Fig-
ure 1A), the sequential addition of unlabeled UBI to 15N-labeled
SREBP-1aTAD causes significant changes in both the 1H and
15N chemical shifts for several signals of SREBP-1aTAD in
the 2D 1H-15N-HSQC spectra (Figure 6). In contrast, addition
of unlabeled UBI to either 15N-labeled p53TAD1, VP16N or
GAL4TAD did not induce any significant changes in their signals
in the 2D 1H-15N-HSQC spectra (Figure S5). Based on these
results, it appears that only select acidic TADs that function as
activation-degradation regions have the capacity to bind nonco-
valently to UBI as part of their function and this includes
SREBP1a and EKLFTAD1.
DISCUSSION
Hematopoietic development requires that cell-specific factors
participate in a complex network of macromolecular interactions
in order to activate lineage-specific expression programs while
simultaneously repressing expression of alternative blood line-
ages. Given the complexity of the process, precise functioning
levels of hematopoietic-specific transcription factors are
required and this can be achieved through different mechanisms
including controlling rates of gene expression and/or rates of
proteolytic degradation. In this article, we examine the mecha-
nism of ubiquitin-mediated degradation of the erythroid-specific
transcription factor EKLF. Previous studies have shown that
EKLF levels are predominantly regulated by UBI-mediated pro-
teolysis (Quadrini and Bieker, 2006). In addition, a PEST region
located within the minimal TAD of EKLF plays a significant role
in its stability suggesting that this domain has both activation
and degradation functions (Quadrini and Bieker, 2006). We verify
that the minimal TAD of EKLF is essential for its degradation and
demonstrate that EKLFTAD1 within this region forms a direct
noncovalent protein-protein interaction with UBI. NMR structural
studies of the EKLFTAD1-UBI complex show that EKLFTAD1Structure 21, 2014–20adopts a 14-residue amphipathic a helix when bound to UBI,
and this helix interacts with UBI in a manner similar to the MUI
domain of Rabex5 (Lee et al., 2006; Penengo et al., 2006).
Studies with TADs from several other proteins demonstrate
that binding to UBI is not a universal attribute for activation-
degradation regions, because only the activation-degradation
regions of EKLF and SREBP1a appear to form a direct interac-
tion with UBI.
The NMR structure of the EKLFTAD1-UBI complex demon-
strates that EKLFTAD1 binds along the Leu8-Ile44-Val70 hydro-
phobic patch of UBI in a similar manner as the MUI of Rabex5
(Lee et al., 2006; Penengo et al., 2006). The structures of
EKLFTAD1-UBI and Rabex5 MIU-UBI are very similar to the
NMR structure of the UIMof Vsp27 bound toUBI with the notable
exception that the a helix of Vsp27-UIM binds UBI in a reverse
orientations with respect to its N and C termini (Lee et al.,
2006; Penengo et al., 2006; Swanson et al., 2003). Therefore, it
is interesting to compare the EKLF-UBI structure with both the
Rabex5-UBI structure and the Vsp27-UBI structure. Aligning
the sequences from the UBI-interacting helices of EKLF, Rabex5
and Vsp27 (Figure 7A), it appears there is a consensus motif of
X-X-a-f-f-X-X-f-X-X-a-a, where ‘‘a’’ is an acidic residue (Asp
or Glu) and ‘‘f’’ is a hydrophobic residue. In addition, the super-
position of the three interacting helices in complex with UBI indi-
cates that they are very similar to each other (Figure 7B). For all
three UBI-interacting helices, the hydrophobic residue in posi-
tion five of the helix makes direct contacts with the Leu8-Ile44-
Val70 hydrophobic patch of UBI. In the case of Rabex5 and
Vsp27, this residue is an Ala (Ala58 and Ala266, respectively),
whereas in EKLF this corresponds to Leu28. The superposition
of the EKLF-UBI and Rabex5-UBI structures demonstrates that
one of themethyl groups of Leu28 from EKLF is in a similar orien-
tation along the surface of UBI as the methyl group of Ala58 from
Rabex5 (Figure 7C). In both cases, the methyl groups are in
position to form methyl-methyl contacts with the side chains of
Ile44 and Val70 of UBI. The other key residue for the interaction
of EKLF, Rabex5, and Vps27 helices with UBI is the hydrophobic
residue in position eight of the helix. This residue corresponds
to Leu61 in Rabex5, Ile263 in Vps27, and Trp31 in EKLF and in
all cases it is inserted into a large pocket formed by Leu8,
Arg42, Ile44, Gln49, Val70, and Arg72. Superimposing the
EKLF-UBI and Rabex5-UBI structures shows that the side
chains of Leu61 of Rabex5 and Trp31 of EKLF are positioned
in almost the same location on the surface of UBI (Figure 7D).24, November 5, 2013 ª2013 Elsevier Ltd All rights reserved 2019
AW31L28
C
W31
E35
R72
I44
L8
V70
B
D25
L28
K6
L8
H68
I44
Figure 4. Structural Details of the EKLFTAD1-UBI Interface
(A) The backbone of EKLFTAD1 (magenta) is represented as a ribbon whereas
UBI is shown as a molecular surface (cyan). The side chains of Phe27, Leu28,
and Trp31 from the hydrophobic face of EKLFTAD1a helix are shown as
sticks. Trp31 of EKLFTAD1 is shown inserted into a shallow pocket formed
by Leu8, Arg42, Ile44, Gln49, Val70, and Arg72 of UBI and Leu28 of EKLFTAD1
is shown inserted into a pocket formed by Lys6, Leu8, Ile44, His68, and
Val70 of UBI.
Figure 5. TheMinimal TAD of EKLF Functions as a ‘‘Degron’’ in Cells
(A) Luciferase activity measured in C33A cells transfected with increasing
amounts of either the EKLF-RLuc, DTAD-EKLF-RLuc, or F27S/L28S/W31S-
EKLF-RLuc expression vector. For each measurement, the levels of RLuc
activity were normalized to those of FLuc expressed from a cotransfected
plasmid.
(B) Bar graph showing the expression slopes of EKLF, DTAD-EKLF, and F27S/
L28S/W31S-EKLF calculated from the data in (A). SDs from quadruplicate
values are indicated as error bars, but in some cases are too small to be visible.
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2020 Structure 21, 2014–2024, November 5, 2013 ª2013 Elsevier LtdIn comparison with the UBI-interacting helices of Rabex5 and
Vps27, the a helix of EKLF is slightly shifted relative to UBI due
to the presence of the bulkier Trp31 side chain (Figure 7B).
This small shift allows for the correct positioning of the aromatic
ring of Trp31 as well as the other methyl group of Leu28 in the
Leu8-Ile44-Val70 hydrophobic patch of UBI.
A number of mechanisms have been proposed to account for
the overlapping activation/degradation functions associated
with the acidic TAD of several transcriptional regulatory proteins
(Bhat and Greer, 2011; Geng et al., 2012; Kodadek, 2010;
Kodadek et al., 2006). Our results here suggest that the(B and C) The backbone of EKLFTAD1 and UBI are represented as ribbons.
The side chains of Lys6, Leu8, Ile44, and Val70 of UBI as well as Asp25 and
Leu28 of EKLFTAD1 are shown as sticks in (B). The side chain of Leu28 of
EKLFTAD1 is in position to formmethyl-methyl contacts with the side chains of
Leu8 and Ile44 of UBI. In addition, the carboxyl group of Asp25 from
EKLFTAD1 is in position to form a salt bridge with the amino group from
the side chain of Lys6 of UBI. In (C), the side chains of residues Leu8, Ile44,
Val70, and Arg72 of UBI and Phe27, Trp31, and Glu35 of EKLFTAD1 are
shown as sticks. The indole ring of Trp31 of EKLFTAD1 interacts with methyl
groups of Leu8, Ile44, and Val70 of UBI and the carboxyl group of Glu35
of EKLFTAD1 is in position to form an ionic interaction with the guanidino
group of Arg72 of UBI.
See also Figures S2–S4.
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Figure 6. The Acidic TAD of SREBP-1a Binds to UBI
Overlay of the 2D 1H-15N HSQC spectra of 15N-labeled SREBP-1aTAD in the
free form (black) or in the presence of one (pink), two (blue), three (orange), four
(green), and five (red) molar equivalents of UBI.
See also Figures S5 and S6.
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The Acidic TAD of EKLF Directly Binds Ubiquitinactivation-degradation regions of EKLF and SREBP1amay func-
tion in similar manners in part through their ability to form a direct
noncovalent protein-protein interaction with UBI. This mecha-
nism would be distinct from what is observed for the activa-
tion-degradation regions of p53, VP16, and Gal4, which do not
appear to form a noncovalent interaction with UBI. The activa-
tion-degradation regions of p53, VP16, and Gal4 have all been
shown to form direct interactions with their respective UBI E3-
ligases. In all three cases, the binding to the E3 ligase enhances
ubiquitination, activation, and degradation via the UPS (Archer
et al., 2008; Haupt et al., 1997; Kubbutat et al., 1997; Le Cam
et al., 2006; Muratani et al., 2005; Salghetti et al., 2001). For
both SREBP1a and EKLF, the role of their acidic N-terminal
activation-degradation regions appears to be more complex. In
the case of SREBP1a, it must first bind to DNA to initiate the
activation/degradation process (Punga et al., 2006). Once bound
to DNA, SREBP1a is phosphorylated on a number of serine res-
idues near its C terminus, which leads to the recruitment of its E3
ligase Fbw7 (Bengoechea-Alonso and Ericsson, 2009; Punga
et al., 2006; Sundqvist et al., 2005). EKLF does not appear to
contain a sequence similar to the phosphorylation region found
in SREBP1a, but a recent study demonstrated that the PEST1
region in EKLTAD forms a direct interaction with the Ppm1b
phosphatase (Yien and Bieker, 2012). Currently, the E3 ligase
or ligases responsible for EKLF ubiquitination have not yet
been identified, although it is known that EKLF is ubiquitinatedStructure 21, 2014–20at several lysine residues and deletion of the PEST1 region
appears to result in a slight hyperubiquitination (Quadrini and
Bieker, 2006).
In conclusion, the precise role of the activation-degradation
regions of EKLF in regulating its activation and degradation func-
tions is clearly complex, but it appears that its ability to form non-
covalent interactions with UBI may be essential to these roles.
For both EKLF and SREBP1a, deletion studies demonstrate
that these activation-degradation regions are not essential for
their ubiquitination (Quadrini and Bieker, 2006; Sundqvist and
Ericsson, 2003). This would indicate that these regions do not
function by stabilizing an interaction with an UBI-charged E2-
conjugating enzyme that leads to mono-ubiquitination indepen-
dent of an E3 ligase as has been demonstrated for other proteins
containing UBDs (Hoeller et al., 2007). One possible explanation
is that the activation-degradation regions of EKLF and SREBP1a
function by forming either an interaction with ubiquitinated
transcriptional regulatory proteins (Geng et al., 2012) or an inter-
molecular interaction with one of their own ubiquitinated lysine
residues (Hoeller et al., 2006) that is important both for their acti-
vation and degradation functions. Such noncovalent binding to
ubiquitinated proteins has been suggested to be the functional
role of the MUI domain of Rabex5 (Mattera and Bonifacino,
2008). However, additional studies are needed to more clearly
define the role of the noncovalent interaction between UBI and
the activation-degradation regions of EKLF and SREBP1a in
regulating their transcriptional activity and degradation.
EXPERIMENTAL PROCEDURES
Cloning of EKLF-RLuc Constructs
The plasmid for expressing EKLF-RLuc was prepared starting with the cDNA
of human EKLF provided by Dr. James Bieker (Mount Sinai Hospital, New
York, NY). This was cloned into pRLuc in order to express full-length EKLF
(residues 1–363) as a fusion protein with Renilla luciferase at the C terminus
of the protein. The DTAD-EKLF-RLuc (EKLF residues 91–363 fused to RLuc)
and F27S/L28S/W31S-EKLF-RLuc (EKLF with serine substitutions at Phe27,
Leu28, and Trp31 fused to RLuc) expression plasmids were prepared by dele-
tion or mutation of the EKLF-RLuc plasmid. All plasmids were sequenced to
confirm their identity.
EKLF Stability Assay
Increasing amounts of plasmids encoding EKLF-RLuc, DTAD-EKLF-RLuc, or
F27S/L28S/W31S-EKLF-RLuc were cotransfected with a constant amount
of FLuc normalization plasmid (2.5 ng) into 2.5 3 104 C33a cells in white 96-
well plates. For each transfection, the total amount of transfected DNA was
kept constant by the addition of the appropriate empty vector. Twenty-four
hours after transfection, FLuc and RLuc activities were measured using the
Dual-Glo luciferase system (Promega) and a GloMax 96-well luminometer
(Promega) according to the instructions from the manufacturer. For each
construct, five different amounts of expression vector (6.25, 12.5, 25, 50,
100 ng) were tested in triplicates and in two separate experiments. The error
bars represent SD.
Statistical Analysis
For the EKLF stability assay, linear regression analysis of all 30 values was
used to calculate a slope diagnostic of the expression/stability of each EKLF
construct. Standard deviations from quadruplicate values are indicated as
error bars.
Cloning, Expression, and Purification of Recombinant Proteins
The EKLFTAD (residues 1–90 of hEKLF), EKLFTAD1 (residues 1–40 of hEKLF),
EKLFTAD (residues 50–90 of hEKLF), p53TAD1 (residues 1–40 of human p53),24, November 5, 2013 ª2013 Elsevier Ltd All rights reserved 2021
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Figure 7. Sequence and Structure Compar-
ison of the UBI-Interacting Helices from
EKLFTAD1, Rabex5, and Vps27
(A) Sequence alignment of the UBI-interacting
helix of EKLFTAD1 with that of the MUI of Rabex5
and UIM of Vps27. Note that the Vps27 sequence
is aligned in the inverse orientation relative to
EKLFTAD1 and Rabex5 in accordance with its
inverse orientation in complex with UBI. In the
consensus sequence, ‘‘f’’ represents a hydro-
phobic amino acid residue, ‘‘a’’ an acidic amino
acid residue, and ‘‘x’’ any amino acid residue.
(B) Overlay of the ribbon structures of EKLFTAD1
(magenta), Rabex5 (green; PDB accession code:
2C7N) and Vps27 (red; PDB accession code:
1Q0W) in complex with UBI (cyan). The a helices of
EKLFTAD1 and Rabex5 are in the same orientation
(N terminus to C terminus), whereas the a helix of
Vps27 is in the reverse orientation.
(C and D) Overlay of the ribbon structures of
UBI (cyan) and the UBI-interacting helices of
EKLFTAD1 (magenta) and Rabex5 (green). The
side chains of Leu28 from EKLFTAD1 and Ala58
from Rabex5 are shown as sticks inserting in a
similar manner into a pocket formed by Ile44 and
Val70 of UBI in (C). In (D), the side chains of Phe27
and Trp31 from EKLFTAD1 and Leu57 and Leu61
from Rabex5 are shown as sticks inserting into a
pocket formed by Leu8, Ile44, and Val70 of UBI in a
similar manner.
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The Acidic TAD of EKLF Directly Binds UbiquitinVP16N (residues 412–456 of herpes simplex virus protein 16), SREBP1aTAD
(residues 1–50 of human SREBP1a), and Gal4TAD (residues 851–881 of
GAL4) proteins were all cloned into the pGEX-2T vector (GE Healthcare). Point
mutants of EKLFTAD1 were generated using the QuikChange Mutagenesis Kit
(Stratagene). All proteins were expressed as GST-fusion proteins in Escheri-
chia coli host strain TOPP2, bound to GSH resin (GE Healthcare), cleaved
with thrombin, and purified over a Q-Sepharose column as previously
described (Di Lello et al., 2005). UBI was purified as described (Sass et al.,
1999). The UBI44A protein (UBI with I44A substitution) was generated using
the QuikChange Mutagenesis Kit and purified as described for UBI. 15N-
labeled and 15N/13C-labeled proteins were prepared in media containing
15NH4Cl and/or
13C6-glucose as the sole nitrogen and carbon sources.
NMR Samples
NMR samples for titrations consisted in 0.4 mM of 15N-UBI in 20 mM sodium
phosphate buffer (pH 6.5) [90%H2O/10% D2O] and unlabeled proteins
(EKLFTAD, EKLFTAD1, and EKLFTAD2) were added in stepwise increments.
The same experimental conditions were used for titration of the 15N-labeled
TAD proteins with either unlabeled UBI or UBI44A. For NMR structural studies
of the EKLFTAD1-UBI complex, four samples were prepared in 20mM sodium
phosphate buffer (pH 6.5) [90%H2O/10%D2O or 100%D2O]: 0.8 mM of either
15N-labeled UBI and 4.0 mM unlabeled EKLFTAD1, 0.8 mM 15N/13C-labeled
UBI and 4.0 mM unlabeled EKLFTAD1, 0.8 mM 15N-labeled EKLFTAD1 and
4.0 mM of unlabeled UBI, or 0.8 mM 15N/13C-labeled EKLFTAD1 and
4.0 mM of unlabeled UBI.
NMR Spectroscopy
NMR spectra were collected at 300 K on Varian Unity Inova 500, 600, and
800 MHz spectrometers. The backbone and aliphatic side chain resonances
(1H, 15N, and 13C) were assigned by a series of triple resonance experiments
(HNCO (Kay et al., 1994), HNCACB (Wittekind and Mueller, 1993),
(HB)CBCA(CO)NNH (Grzesiek and Bax, 1992), C(CO)NNH (Logan et al.,
1992), H(CCO)NNH (Logan et al., 1992), and HCCH-COSY (Ikura et al.,
1991)]. Distance restraints were obtained from 15N-edited NOESY-HSQC2022 Structure 21, 2014–2024, November 5, 2013 ª2013 Elsevier Ltdand 13C-edited NOESY-HSQC experiments (90 ms mixing time). Intermolec-
ular NOEs were obtained from a 3D 15N, 13C (F1)-filtered, (F3)-NOESY-
HSQC (Zwahlen et al., 1997). NMR data were processed by NMRPipe/
NMRDraw (Delaglio et al., 1995) and analyzed with CcpNmr analysis (Vranken
et al., 2005).
Structure Calculations
Structure calculations were performed with the program CNS using a combi-
nation of torsion angle dynamics and Cartesian dynamics (Bru¨nger et al.,
1998). The backbone dihedral angles were obtained using the program TALOS
(Cornilescu et al., 1999). Starting from an extended structure with standard
geometry, 50 conformers were calculated satisfying all the experimental con-
straints with no NOE violation >0.2 A˚ and no dihedral angle violations >2. The
quality of the structures was analyzed using PROCHECK-NMR (Laskowski
et al., 1996) and MOLMOL (Koradi et al., 1996). All of the figures representing
the structures were generated with the program PyMOL.
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